Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials

dc.contributor.author	O'Byrne, Ken
dc.date.accessioned	2018-10-09T10:39:34Z
dc.date.available	2018-10-09T10:39:34Z
dc.date.issued	2018
dc.date.submitted	2018	en
dc.identifier.citation	Wu, Y.-L. and Sequist, L.V. and Tan, E.-H. and Geater, S.L. and Orlov, S. and Zhang, L. and Lee, K.H. and Tsai, C.-M. and Kato, T. and Barrios, C.H. and Schuler, M. and Hirsh, V. and Yamamoto, N. and O'Byrne, K. and Boyer, M. and Mok, T. and Peil, B. and M??rten, A. and Chih-Hsin Yang, J. and Paz-Ares, L. and Park, K., Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials, Clinical Lung Cancer, 19, 4, 2018, e465-e479	en
dc.identifier.other	Y
dc.format.extent	e465-e479	en
dc.language.iso	en	en
dc.relation.ispartofseries	Clinical Lung Cancer;
dc.relation.ispartofseries	19;
dc.relation.ispartofseries	4;
dc.rights	Y	en
dc.subject	Afatinib	en
dc.title	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials	en
dc.type	Journal Article	en
dc.type.supercollection	scholarly_publications	en
dc.type.supercollection	refereed_publications	en
dc.identifier.peoplefinderurl	http://people.tcd.ie/obyrneke
dc.identifier.rssinternalid	192353
dc.identifier.doi	http://dx.doi.org/10.1016/j.cllc.2018.03.009
dc.rights.ecaccessrights	openAccess
dc.identifier.uri	http://hdl.handle.net/2262/85084

Browse